Topic: Capecitabine (Xeloda) for metastatic breast cancer

Author：

ISSN： 1475-9896

Source： Journal of Clinical Excellence, Vol.4, Iss.4, 2002-09, pp. : 425-428

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Xeloda^® in the Treatment of Metastatic Breast Cancer

Oncology, Vol. 57, Iss. 1, 1999-07 ,pp. : 16-20

Karger

Access to resources Recommend Favorite

Quality of Life under Capecitabine (Xeloda®) in Patients with Metastatic Breast Cancer: Data from a German Non-Interventional Surveillance Study

Oncology Research and Treatment, Vol. 37, Iss. 12, 2014-11 ,pp. : 748-755

Karger

Access to resources Recommend Favorite

Dose-Finding Phase I and Pharmacokinetic Study of Capecitabine (Xeloda) in Combination with Epirubicin and Cyclophosphamide (CEX) in Patients with Inoperable or Metastatic Breast Cancer

Oncology, Vol. 72, Iss. 5-6, 2008-01 ,pp. : 330-337

Karger

Access to resources Recommend Favorite

Capecitabine for the oral treatment of metastatic breast cancer

By Cortés-Funes Hernán

Women's Health, Vol. 2, Iss. 6, 2006-11 ,pp. : 805-817

Future Medicine

Access to resources Recommend Favorite

Is Capecitabine Efficacious in Triple Negative Metastatic Breast Cancer?

Oncology, Vol. 79, Iss. 5-6, 2011-03 ,pp. : 331-336

Karger

Access to resources Recommend Favorite